Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.67 |
| ▸ | MMP13 | P45452 | 15/20 | 0.67 |
| ▸ | MMP1 | P03956 | 11/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416696 | 0.89 | MMP13 (0.67) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL7412264 | 0.88 | MMP13 (0.60) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL7412150 | 0.78 | MMP13 (0.60) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL231737 | 0.74 | MMP1 (0.55) | MMP2MMP13MMP1MMP9LTA4H | |
| SCHEMBL6769491 | 0.71 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL6767563 | 0.71 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL6767568 | 0.71 | MMP13 (0.77) | MMP2MMP13MMP1 | |
| SCHEMBL7210912 | 0.70 | MMP1 (0.51) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL4652358 | 0.69 | MMP1 (1.00) | MMP2MMP13MMP1MMP9 | |
| SCHEMBL7299694 | 0.69 | MMP13 (0.62) | MMP2MMP13MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| US-7122548-B2 | Triazolotriazine compounds and uses thereof | SUGEN, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1483268-A2 | INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MMP2 3649/4885MMP13 3375/4885MMP1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.